• About ARCA
  • Our Science
  • Clinical Trials
  • Collaborations
  • Investors
  • Contact Us

JACOB MA-WEAVER JOINS ARCA BIOPHARMA BOARD OF DIRECTORS

Posted on June 21, 2022 by Derek - Press Release, Uncategorized

6.21-Jacob-Ma-Weaver-Joins-BOD-FINAL

ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

Posted on May 5, 2022 by Derek - Press Release, Uncategorized

5.4-ARCA-Retains-Ladenburg-Thalmann

ARCA biopharma Announces First Quarter 2022 Financial Results

Posted on May 2, 2022 by Derek - Press Release, Uncategorized

5.2-2022-Q1-Financial-Results-and-Business-Update

ARCA biopharma Establishes Special Committee of the Board of Directors

Posted on April 18, 2022 by Derek - Press Release, Uncategorized

4.18-BOD-Strategic-Planning-Committee

ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2B Clinical Trial

Posted on March 31, 2022 by Derek - Press Release, Uncategorized

3.31-ASPEN-COVID-19-Phase-2B-Data-FINAL

ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update

Posted on March 14, 2022 by Derek - Press Release, Uncategorized

3.14-2021-Financial-Results-and-Business-Update

Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

Posted on January 4, 2022 by Derek - Press Release, Uncategorized

1.4-Gencaro-Data-Published-in-Heart-Rhythm-O2

ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19

Posted on December 2, 2021 by Derek - Press Release, Uncategorized

12.2-ASPEN-COVID-19-trial-enrollment-completion

ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th

Posted on November 9, 2021 by Derek - Press Release, Uncategorized

11.9-Q4-Virtual-Investor-Summit-Annc-FINAL

ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Posted on November 2, 2021 by Derek - Press Release, Uncategorized

11.2-3Q2021-Financial-Results-and-Business-Update

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next
  • Last

Recent Posts

  • JACOB MA-WEAVER JOINS ARCA BIOPHARMA BOARD OF DIRECTORS
  • ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
  • ARCA biopharma Announces First Quarter 2022 Financial Results
  • ARCA biopharma Establishes Special Committee of the Board of Directors
  • ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2B Clinical Trial

Archives

  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • May 2021
  • March 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • February 2020
  • November 2019
  • September 2019
  • August 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • December 2018
  • November 2018
  • September 2018
  • August 2018
  • July 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • November 2017
  • September 2017
  • August 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • November 2016
  • October 2016
  • August 2016
  • May 2016
  • April 2016
  • March 2016
  • January 2016
  • November 2015
  • September 2015
  • August 2015
  • June 2015

Categories

  • Press Release
  • Uncategorized
ARCA Biopharma Logo
  • 720-940-2100
  • 10170 Church Ranch Way, Suite 100
  • Westminster, CO 80021
  • About ARCA
  • Our Science
Slash
  • Clinical Trials
  • Collaborations
Slash
  • Investors
  • Contact
    • © 2022 ARCA Biopharma.

    • Slash
      • Sitemap
      • Legal Disclaimer
Designed by Watermark